




# PHARMACEUTICAL 2020

Corvus Pharmaceuticals Inc.  
Rank 104 of 358





## PHARMACEUTICAL 2020

Corvus Pharmaceuticals Inc.  
Rank 104 of 358

The relative strengths and weaknesses of Corvus Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corvus Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 102% points. The greatest weakness of Corvus Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 157%, being 121% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	79,344
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,225
Liabilities, Non-Current	2,310
Other Assets	2,840
Other Compr. Net Income	63
Other Expenses	0
Other Liabilities	0
Other Net Income	2,182
Other Revenues	0
Property and Equipment	1,462
Research and Development	37,975
Selling, General and Administrative Expense	10,879

Output Variable	Value in 1000 USD
Assets	83,646
Liabilities	12,535
Expenses	48,854
Revenues	0
Stockholders Equity	71,111
Net Income	-46,672
Comprehensive Net Income	-46,640
Economic Capital Ratio	157%